Drugs / ARO-INHBE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06700538 | Dec 2024 → Sep 2027 expected | obesity disorder | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07859813 | Sep 2026 → Oct 2029 expected | metabolic dysfunction-associated steatohepatitis | Arrowhead Pharmaceuticals | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 arrowheadpharma.com ↗
ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in individuals with obesity with or without Type 2 Diabetes Mellitus (T2DM) |
| 2026-01-06 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition arrowheadpharma.com ↗
ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide alone |
| 2025-03-06 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases arrowheadpharma.com ↗
In a diet-induced obese (DIO) mouse model, hepatic INHBE silencing with siRNA led to a 19% suppression in body weight gain relative to vehicle controls. |
| 2024-09-23 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-INHBE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07859813 ↗ |
| Route | Subcutaneous | “Subcutaneous (SC) injection” NCT06700538 ↗ |